公开(公告)号：US20190038728A1

公开(公告)日：2019-02-07

申请号：US16058257

申请日：2018-08-08

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Helen Kim Cho ,  Michael Robert Dermyer ,  Karin Ute Jooss ,  Brian Gregory Pierce ,  Joyce Tsi Tan ,  Van To Tsai ,  James Richard Merson

IPC: A61K39/00 ,  A61K9/00 ,  C12N9/48 ,  C12N9/64 ,  A61K31/404 ,  A61K31/7088 ,  A61K39/39 ,  C07K16/30 ,  C07K16/28 ,  C07K14/47 ,  A61K39/395

Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.

公开(公告)号：US20230201283A1

公开(公告)日：2023-06-29

申请号：US17790160

申请日：2021-01-05

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Michael Dale Eisenbraun ,  Douglas Hanahan ,  David H. Kirn ,  Clare Lees ,  Prajit Limsirichai ,  Liliana Maruri Avidal

IPC: A61K35/768 ,  C12N15/86 ,  A61K39/395 ,  C07K14/55 ,  C12N9/12 ,  A61P35/00

CPC classification number: A61K35/768 ,  A61K39/3955 ,  A61P35/00 ,  C07K14/55 ,  C12N9/1211 ,  C12N15/86 ,  C12Y207/01021 ,  C12N2710/24132 ,  C12N2710/24143

Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus (RVV), compositions comprising the RVV, and use of the RVV or composition for inducing oncolysis in an individual having a tumor.

公开(公告)号：US20220033784A1

公开(公告)日：2022-02-03

申请号：US17371206

申请日：2021-07-09

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Michael Dale Eisenbraun ,  Clare Lees ,  Jeremy Shawn Myers ,  James Travis Patterson

IPC: C12N7/00 ,  C07K14/55 ,  A61K35/768 ,  A61P35/00

Abstract: The present disclosure provides human IL-2 variants, recombinant oncolytic viruses comprising the IL-2 variant, compositions comprising the IL-2 variant or recombinant oncolytic virus, and use of the IL-2 variants, recombinant oncolytic virus, or compositions for treating cancer in an individual.

公开(公告)号：US11110158B2

公开(公告)日：2021-09-07

申请号：US16058257

申请日：2018-08-08

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Helen Kim Cho ,  Michael Robert Dermyer ,  Karin Ute Jooss ,  Brian Gregory Pierce ,  Joyce Tsi Tan ,  Van To Tsai ,  James Richard Merson

IPC: A61K39/00 ,  C07K14/47 ,  C12N9/48 ,  A61K39/39 ,  A61K39/395 ,  A61K31/404 ,  C12N9/64 ,  A61K9/00 ,  A61K31/7088 ,  C07K16/28 ,  C07K16/30

Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.

公开(公告)号：US10092636B2

公开(公告)日：2018-10-09

申请号：US15146578

申请日：2016-05-04

Applicant: Pfizer Inc.

Inventor： Joseph John Binder

IPC: A61K39/00 ,  A61K31/404 ,  A61K31/7088 ,  A61K39/395 ,  C07K16/28 ,  C07K14/705 ,  C12N9/64 ,  A61K45/06 ,  A61K31/436 ,  A61K31/44 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377

Abstract: The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.

公开(公告)号：US09402901B2

公开(公告)日：2016-08-02

申请号：US14527226

申请日：2014-10-29

Applicant: Pfizer Inc.

Inventor： Joseph John Binder

IPC: A61K39/12 ,  A61K39/395 ,  A61K31/404 ,  A61K31/7088 ,  C12N7/00 ,  A61K39/00

CPC classification number: A61K39/0011 ,  A61K31/404 ,  A61K31/436 ,  A61K31/44 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/7088 ,  A61K39/00 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/55561 ,  A61K2039/645 ,  A61K2039/70 ,  C07K14/705 ,  C07K16/2818 ,  C07K16/2878 ,  C07K2317/75 ,  C07K2319/40 ,  C12N7/00 ,  C12N9/6424 ,  C12N2710/10343 ,  C12N2710/10371 ,  C12N2830/006 ,  C12N2840/20 ,  C12N2840/203 ,  C12Y304/21077 ,  A61K2300/00

Abstract: The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.

Abstract translation: 本公开提供（a）载体，其包含编码两种，三种或更多种免疫原性PAA多肽的多抗原构建体; （b）包含载体的组合物，（c）涉及用于引发免疫应答或用于治疗前列腺癌的载体和组合物的用途的方法。